Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 4, 2005, Pages 218-228

  Pearson, Thomas A ^a   Denke, Margo ^b   McBride, Patrick ^c   Battisti, Wendy P ^d   Brady, William E ^d   Palmisano, Joanne ^d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination therapy; Elderly; Ezetimibe; Simvastatin; Stain

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GROUPS BY AGE; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 33144467868     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2005.12.009     Document Type: Article

References (29)

1. American Heart Association Heart Disease and Stroke Statistics-2005 Update 2005 American Heart Association Dallas, Tex
2. Grundy S.M. The role of cholesterol management in coronary disease risk reduction in elderly patients Endocrinol Metab Clin North Am 27 1998 655-675
3. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo controlled trial Lancet 360 2002 7-22
4. Sacks F.M. Pfeffer M.A. Moye L.A. et al. Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001-1009
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383-1389
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels N Engl J Med 339 1998 1349-1357
7. Collins R. Armitage J. Parish S. et al. Heart Protection Study Collaborative Group Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or otherhigh-risk conditions Lancet 363 2004 757-767
8. Lewis S.J. Moye L.A. Sacks F.M. et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results ofthe Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 1998 681-689
9. Miettinen T.A. Pyorala K. Olsson A.G. et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S) Circulation 96 1997 4211-4218
10. Shepherd J. Blauw G.J. Murphy M.B. et al. PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet 360 2002 1623-1630
11. Gaw A. The care gap: Underuse of statin therapy in the elderly Int J Clin Pract 58 2004 777-785
12. Ko D.T. Mamdani M. Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox JAMA 291 2004 1864-1870
13. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk Cardiovasc Drugs Ther 17 2003 265-285
14. Moghadasian M.H. A safety look at currently available statins Expert Opin Drug Saf 1 2002 269-274
15. Andrews T.C. Ballantyne C.M. Hsia J.A. Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins Am J Med 111 2001 185-191
16. Foley K.A. Simpson R.J. Jr Crouse J.R. III et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events Am J Cardiol 92 2003 79-81
17. Pearson T.A. Denke M.A. McBride P.E. et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemicpatients: The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial Mayo Clin Proc 80 2005 587-595
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486-2497
19. Gagne C. Bays H.E. Weiss S.R. et al. Ezetimibe Study Group Efficacy and safety of ezefmibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia Am J Cardiol 90 2002 1084-1091
20. LaRosa J.C. He J. Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials JAMA 282 1999 2340-2346
21. Fonarow G.C. French W.J. Parsons L.S. et al. Use of fipidlowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3 Circulation 103 2001 38-44
22. Mungall M.M. Gaw A. Statin therapy in the elderly Curr Opin Lipidol 15 2004 453-457
23. Lipka L. Sager P. Strony J. et al. Ezetimibe Study Group Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia Drugs Aging 21 2004 1025-1032
24. Arici M. Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59 2001 407-414
25. Ridker P.M. Rifai N. Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557-1565
26. Ridker P.M. Cannon C.P. Morrow D. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22(PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20-28
27. Pearson T.A. Mensah G.A. Alexander R.W. et al. Centers for Disease Control and Prevention and the American Heart Association Markers of inflammation and cardiovascular dis ease: Application to clinical and public health practice: A statement for healthcare professionalsfrom the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499-511
28. Aronow W.S. Hypercholesterolemia. The evidence supports use of statins Geriatrics 58 2003 18-32
29. [published correction appears in Circulation. 2004;110:763]. Grundy S.M. Cleeman J.I. Merz C.N. et al. National Heart, Lung, and Blood Institute, the American College of Cardiology Foundation, and the American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227-239